Last 27 quarters of trend data · Healthcare · Healthcare Providers
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.44 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.06 | 0.39 | 0.84 | 1.23 | 1.25 | 1.88 | 2.03 | 1.71 | 1.12 | 0.44 | 0.82 | 1.76 | 0.44 | 1.12 | 0.55 | 0.59 | 0.81 | 1.64 | 3.90 | 2.95 | 4.63 |
| — | -79.3% | -58.6% | -27.8% | +12.0% | +325.2% | +149.1% | -2.7% | +156.9% | -60.7% | +48.8% | +199.9% | -46.4% | -31.3% | -86.0% | -80.1% | -82.4% | -71.3% | -55.5% | -52.2% | — | |
| P/B Ratio | — | — | — | — | 13.42 | 6.27 | 5.56 | 3.18 | 2.25 | 1.13 | 19.16 | 55.51 | 124.93 | 7.25 | 1.21 | 1.93 | 1.40 | 1.85 | 2.73 | 2.03 | 2.59 |
| — | — | — | — | +495.9% | +454.9% | -71.0% | -94.3% | -98.2% | -84.4% | +1485.3% | +2780.7% | +8820.6% | +292.6% | -55.7% | -5.0% | -46.0% | -34.4% | -67.6% | -57.9% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.4% | 57.3% | 50.7% | 78.1% | 58.0% | 55.2% | 50.0% | 56.7% | 60.5% | 65.4% | 56.7% | 59.7% | 52.9% | 61.8% | 60.6% | 60.4% | 58.8% | 61.9% | 70.0% | 70.7% | 70.0% |
| — | +3.7% | +1.3% | +37.8% | -4.0% | -15.5% | -11.7% | -5.0% | +14.3% | +5.8% | -6.5% | -1.1% | -10.0% | -0.1% | -13.4% | -14.6% | -16.0% | -23.2% | -10.3% | -13.0% | -10.8% | |
| Operating Margin | -114.1% | -93.6% | -128.7% | -166.9% | -69.8% | -127.4% | -129.9% | -75.9% | -68.5% | -47.8% | -110.7% | -131.9% | -110.3% | -133.0% | -129.8% | -153.5% | -127.3% | -166.4% | -182.2% | -168.7% | -121.1% |
| — | +26.5% | +1.0% | -119.9% | -1.9% | -166.7% | -17.3% | +42.5% | +37.9% | +64.1% | +14.7% | +14.1% | +13.4% | +20.1% | +28.8% | +9.0% | -5.2% | -84.3% | -84.4% | +10.7% | -119.3% | |
| Net Margin | -121.7% | -106.4% | -150.8% | -181.9% | -79.6% | -131.2% | -128.1% | -76.4% | -67.8% | -47.6% | -110.1% | -131.1% | -63.4% | -162.8% | -44.2% | -154.2% | -128.0% | -167.1% | -146.3% | -168.2% | -120.0% |
| — | +18.9% | -17.7% | -137.9% | -17.5% | -175.7% | -16.4% | +41.7% | -6.9% | +70.8% | -149.3% | +14.9% | +50.5% | +2.6% | +69.8% | +8.4% | -6.7% | -85.9% | -48.4% | +11.0% | -117.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -663.0% | — | — | -1416.3% | -151.8% | -111.5% | -62.5% | -36.2% | -37.3% | -55.7% | -757.9% | -1863.9% | -194.5% | -121.5% | -28.9% | -83.1% | -44.0% | -39.2% | -23.0% | -25.5% | -15.8% |
| — | — | — | -3812.5% | -306.5% | -100.2% | +91.8% | +98.1% | +80.8% | +54.2% | -2524.4% | -2143.2% | -342.0% | -210.1% | -25.7% | -226.0% | -178.3% | -146.2% | -5.7% | +69.4% | — | |
| ROA | -105.0% | -22.3% | -30.9% | -27.4% | -20.9% | -26.9% | -29.1% | -18.5% | -16.8% | -14.0% | -33.4% | -40.5% | -17.4% | -35.8% | -11.1% | -37.9% | -25.4% | -25.9% | -16.9% | -19.8% | -12.5% |
| — | +17.1% | -6.2% | -48.3% | -24.6% | -92.4% | +12.9% | +54.4% | +3.6% | +61.0% | -202.2% | -6.7% | +31.5% | -38.2% | +34.4% | -91.6% | -103.1% | -118.4% | -17.3% | +46.5% | +46.9% | |
| ROIC | -227.3% | -47.4% | -52.7% | -43.8% | -30.0% | -47.9% | -88.1% | -67.9% | -94.4% | -273.7% | -921.7% | -333.8% | -355.2% | -256.9% | -126.0% | -94.0% | -73.3% | -101.2% | -118.9% | -133.3% | -94.3% |
| — | +1.1% | +40.1% | +35.5% | +68.3% | +82.5% | +90.4% | +79.7% | +73.4% | -6.5% | -631.3% | -255.2% | -384.8% | -153.8% | -6.0% | +29.5% | +22.3% | +15.3% | +63.9% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 4.94 | 2.53 | 0.32 | 0.19 | 0.21 | 0.28 | 3.23 | 4.85 | 45.74 | 1.05 | 0.33 | 0.50 | 0.29 | 0.20 | 0.11 | 0.06 | 0.04 |
| — | — | — | — | +2202.8% | +809.2% | -90.2% | -96.1% | -99.5% | -73.5% | +876.8% | +865.8% | +15732.8% | +435.7% | +212.8% | +686.5% | +641.5% | +465.2% | +20.0% | -16.2% | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.24 | 0.21 | 0.27 | 0.24 | 0.78 | 1.05 | 0.77 | 1.50 | 1.44 | 1.18 | 0.45 | 0.34 | 0.28 | 0.63 | 1.09 | 0.80 | 1.63 | 2.32 | 3.15 | 3.64 | 4.15 |
| — | -80.3% | -65.0% | -83.8% | -46.1% | -11.4% | +71.5% | +344.6% | +421.2% | +86.7% | -59.0% | -57.6% | -83.0% | -72.7% | -65.3% | -78.1% | -60.8% | -45.2% | +37.4% | +39.6% | +758.3% | |
| Quick Ratio | 0.24 | 0.21 | 0.27 | 0.24 | 0.78 | 1.05 | 0.77 | 1.50 | 1.44 | 1.18 | 0.45 | 0.34 | 0.28 | 0.63 | 1.09 | 0.80 | 1.63 | 2.32 | 3.15 | 3.64 | 4.16 |
| — | -80.3% | -65.0% | -83.8% | -46.1% | -11.4% | +71.5% | +344.6% | +421.2% | +86.7% | -59.0% | -57.6% | -83.0% | -72.7% | -65.3% | -78.1% | -60.9% | -45.2% | +37.4% | +39.6% | +759.8% | |
| Interest Coverage | — | -4.02 | — | — | — | — | — | — | — | — | — | -1.30 | — | — | — | -187.58 | -200.26 | -248.71 | — | -1768.07 | -580.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 27 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VVOS stock.
Vivos Therapeutics, Inc.'s current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Vivos Therapeutics, Inc.'s current operating margin is -114.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Vivos Therapeutics, Inc.'s business trajectory between earnings reports.